RCKTROCKET PHARMACEUTICALS, INC.
Pharmaceutical Preparations
- Revenue
- $0
- Operating margin
- —
- EBITDA
- −$223M
- 16% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear9% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$167M | −$224M | −$260M | −$273M | −$232M | 15% |
| Net income | −$169M | −$222M | −$246M | −$259M | −$223M | 14% |
| Operating cash flow | −$121M | −$178M | −$195M | −$210M | −$190M | 9.4% |
| Capex | $8M | $8M | $16M | $6M | $440K | 92% |
| Stock-based comp | $29M | $31M | $39M | $44M | $37M | 16% |
| Buybacks | $0 | — | — | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $256K · 1
- Net
- −$256K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $4M | −$328K | 18 | 0 |
| FY2024 | $7M | −$2M | 64 | 114 |
| FY2023 | $8M | $12M | 153 | 115 |